Country
Germany
A Phase 3 trial of a candidate immunotherapy for lung cancer, which was being compared with pembrolizumab, has been discontinued, the sponsor Merck KGaA announced on 20 January.
Full text available to subscribers only. Click here for information on subscribing to MedNous.